New oral therapies for type 2 diabetes

Jonathan Purnell, Irl B. Hirsch

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Over the past few years, several oral agents for the treatment of type 2 diabetes have become available in the United States. Metformin, a biguanide that has been used for decades in other countries throughout the world, improves glycemic control with- out exacerbating hyperinsulinemia or promoting weight gain. This agent has recently been reintroduced in the United States. Acarbose is an alpha-glucosidase inhibitor 'that improves glycemic control by decreasing the intestinal absorption of glucose, thereby decreasing postprandial glucose elevations. The use of metformin and acarbose may be limited by their side effects and potential risks, especially the risk of lactic acidosis with metformin. The third newly available agent, troglitazone, has been shown to improve insulin sensitivity. Combinations of metformin, acarbose and troglitazone may facilitate improved glycemic control without the use of insulin, or they may allow sulfonylurea or insulin dosages to be reduced, in this way minimizing the adverse effects of hyperinsulinemia. Unfortunately, current oral therapies do not prevent the inevitable decline in glycemic control that occurs during the natural history of type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)1835-1842
Number of pages8
JournalAmerican Family Physician
Volume56
Issue number7
StatePublished - 1997
Externally publishedYes

Fingerprint

Metformin
troglitazone
Acarbose
Type 2 Diabetes Mellitus
Hyperinsulinism
Insulin
Biguanides
Glucose
Lactic Acidosis
Intestinal Absorption
Therapeutics
Weight Gain
Insulin Resistance

ASJC Scopus subject areas

  • Medicine(all)

Cite this

New oral therapies for type 2 diabetes. / Purnell, Jonathan; Hirsch, Irl B.

In: American Family Physician, Vol. 56, No. 7, 1997, p. 1835-1842.

Research output: Contribution to journalArticle

Purnell, J & Hirsch, IB 1997, 'New oral therapies for type 2 diabetes', American Family Physician, vol. 56, no. 7, pp. 1835-1842.
Purnell, Jonathan ; Hirsch, Irl B. / New oral therapies for type 2 diabetes. In: American Family Physician. 1997 ; Vol. 56, No. 7. pp. 1835-1842.
@article{add53c4478dc4d57b829b47d2185cb92,
title = "New oral therapies for type 2 diabetes",
abstract = "Over the past few years, several oral agents for the treatment of type 2 diabetes have become available in the United States. Metformin, a biguanide that has been used for decades in other countries throughout the world, improves glycemic control with- out exacerbating hyperinsulinemia or promoting weight gain. This agent has recently been reintroduced in the United States. Acarbose is an alpha-glucosidase inhibitor 'that improves glycemic control by decreasing the intestinal absorption of glucose, thereby decreasing postprandial glucose elevations. The use of metformin and acarbose may be limited by their side effects and potential risks, especially the risk of lactic acidosis with metformin. The third newly available agent, troglitazone, has been shown to improve insulin sensitivity. Combinations of metformin, acarbose and troglitazone may facilitate improved glycemic control without the use of insulin, or they may allow sulfonylurea or insulin dosages to be reduced, in this way minimizing the adverse effects of hyperinsulinemia. Unfortunately, current oral therapies do not prevent the inevitable decline in glycemic control that occurs during the natural history of type 2 diabetes.",
author = "Jonathan Purnell and Hirsch, {Irl B.}",
year = "1997",
language = "English (US)",
volume = "56",
pages = "1835--1842",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "7",

}

TY - JOUR

T1 - New oral therapies for type 2 diabetes

AU - Purnell, Jonathan

AU - Hirsch, Irl B.

PY - 1997

Y1 - 1997

N2 - Over the past few years, several oral agents for the treatment of type 2 diabetes have become available in the United States. Metformin, a biguanide that has been used for decades in other countries throughout the world, improves glycemic control with- out exacerbating hyperinsulinemia or promoting weight gain. This agent has recently been reintroduced in the United States. Acarbose is an alpha-glucosidase inhibitor 'that improves glycemic control by decreasing the intestinal absorption of glucose, thereby decreasing postprandial glucose elevations. The use of metformin and acarbose may be limited by their side effects and potential risks, especially the risk of lactic acidosis with metformin. The third newly available agent, troglitazone, has been shown to improve insulin sensitivity. Combinations of metformin, acarbose and troglitazone may facilitate improved glycemic control without the use of insulin, or they may allow sulfonylurea or insulin dosages to be reduced, in this way minimizing the adverse effects of hyperinsulinemia. Unfortunately, current oral therapies do not prevent the inevitable decline in glycemic control that occurs during the natural history of type 2 diabetes.

AB - Over the past few years, several oral agents for the treatment of type 2 diabetes have become available in the United States. Metformin, a biguanide that has been used for decades in other countries throughout the world, improves glycemic control with- out exacerbating hyperinsulinemia or promoting weight gain. This agent has recently been reintroduced in the United States. Acarbose is an alpha-glucosidase inhibitor 'that improves glycemic control by decreasing the intestinal absorption of glucose, thereby decreasing postprandial glucose elevations. The use of metformin and acarbose may be limited by their side effects and potential risks, especially the risk of lactic acidosis with metformin. The third newly available agent, troglitazone, has been shown to improve insulin sensitivity. Combinations of metformin, acarbose and troglitazone may facilitate improved glycemic control without the use of insulin, or they may allow sulfonylurea or insulin dosages to be reduced, in this way minimizing the adverse effects of hyperinsulinemia. Unfortunately, current oral therapies do not prevent the inevitable decline in glycemic control that occurs during the natural history of type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0030697331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030697331&partnerID=8YFLogxK

M3 - Article

C2 - 9371013

AN - SCOPUS:0030697331

VL - 56

SP - 1835

EP - 1842

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 7

ER -